Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs BIIB 063 (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Biogen
- 17 Apr 2017 Status changed from suspended to discontinued due to pending additional preclinical safety findings in non-human primates.
- 24 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 24 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.